Therapy News and Research

RSS
New technology tricks tumors to eliminate itself through the production of anti-cancer agents

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

New cardiac rehabilitation intervention improves quality of life in hospitalized heart failure patients

New cardiac rehabilitation intervention improves quality of life in hospitalized heart failure patients

‘Kicking you when you’re down’: Many cancer patients pay dearly for parking

‘Kicking you when you’re down’: Many cancer patients pay dearly for parking

Sphere Fluidics announces enhanced Cyto-Mine capability and performance

Sphere Fluidics announces enhanced Cyto-Mine capability and performance

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

UNSW researchers find novel way to attack the 'fortress' surrounding pancreatic tumors

UNSW researchers find novel way to attack the 'fortress' surrounding pancreatic tumors

Nanotechnology and COVID-19 diagnosis and treatment

Nanotechnology and COVID-19 diagnosis and treatment

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

Brief pulses of ultrasound delivered to nerves in renal arteries reduce drug-resistant blood pressure

Brief pulses of ultrasound delivered to nerves in renal arteries reduce drug-resistant blood pressure

Older heart failure patients significantly benefit from tailored cardiac rehab program

Older heart failure patients significantly benefit from tailored cardiac rehab program

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

Unique pre-clinical model enables study of HIV infection and testing of new therapies

Unique pre-clinical model enables study of HIV infection and testing of new therapies

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Researchers evaluate diagnostic criteria for anti-NMDA receptor encephalitis in Japanese children

Researchers evaluate diagnostic criteria for anti-NMDA receptor encephalitis in Japanese children

Novel nanotechnology could change the lives of people living with cystic fibrosis

Novel nanotechnology could change the lives of people living with cystic fibrosis

NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells

NK cells combined with bispecific antibody display potent anti-tumor activity against lymphoma cells

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Comprehensive blood atlas of COVID-19 identifies hallmarks of disease severity

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

New study may help develop senolytic drugs that target senescent immune cells

New study may help develop senolytic drugs that target senescent immune cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.